Lisa Rojkjaer
CIK 1846460 · EVP, Chief Medical Officer · last filed 2026-06-03
Lisa Rojkjaer is an EVP, Chief Medical Officer who has filed 17 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider had shares withheld for taxes covering $25.4K of RIGL on Jun 3, 2026. Across all open-market trades the lifetime net is −$50.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.12M
2
17
-$50.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RIGL | EVP, Chief Medical Officer | 34,003 | $32.85 | $1.12M | $0 | 7 | 2026-06-03 |
| Viracta Therapeutics, Inc. (VIRX) Delisted | Chief Medical Officer | 50,243 | $0.01 | $492 | -$50.8K | 10 | 2023-03-17 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | RIGL | Tax (F) | −850 | -$25.4K | EDGAR |
| 2026-02-19 | RIGL | Grant (A) | +18,894 | $0 | EDGAR |
| 2026-02-12 | RIGL | Tax (F) | −3,758 | -$130.1K | EDGAR |
| 2025-09-17 | RIGL | Grant (A) | — | $0 | EDGAR |
| 2025-03-19 | RIGL | Grant (A) | — | $0 | EDGAR |
| 2025-01-31 | RIGL | Grant (A) | +19,717 | $0 | EDGAR |
| 2024-03-29 | RIGL | Grant (A) | — | $0 | EDGAR |
| 2023-03-17 | Viracta Therapeutics, Inc. (VIRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-02-28 | Viracta Therapeutics, Inc. (VIRX) Delisted | Mixed | +1,971 | -$3.6K | EDGAR |
| 2022-11-29 | Viracta Therapeutics, Inc. (VIRX) Delisted | Mixed | +2,011 | -$5.8K | EDGAR |